Drug makers like Merck and Pfizer have been pouring money into fighting a closely-watched November ballot measure in California that would cap drug prices by preventing state programs like Medicaid from paying more than the federal VA pays for individual drugs. At the end of June, the campaign opposing the measure had $66 million in the bank. But a new poll suggests that the “Yes” campaign, which had just $7 million in cash at the end of June, has the upper hand so far.
Two-thirds of likely voters said they would probably or definitely vote to cap drug prices, according to an online survey of 800 people commissioned by the “Yes” campaign. The drug industry-backed “No” campaign, which argues the measure would create red tape and make it harder for patients to access medications, fired back yesterday. Spokesperson Kathy Fairbanks called the new poll results misleading, noting that the survey didn’t use the specific language that will appear on the November ballot.